NCT06438900Recruiting
Investigating the Link Between Advanced Glycation End Products (AGEs) and Muscle Wasting in Sarcobesity
Fighting Western-diet Derived AGEs to Mitigate Muscle Wasting in Sarcobesity:Observational Study on the Relationship Between AGE Levels and Sarcobesity in an Adult Population Affected by Obesity and Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
The study aims to explore whether a high level of AGEs (Advanced Glycation end products) derived from the diet may mediate diet-related muscle loss in Western-type diet, influencing the onset and progression of sarcopenia, predisposing to earlier and more severe metabolic consequences, including type 2 diabetes (T2D). The primary objective of the study is to investigate how the accumulation of AGEs is correlated with muscle loss in adult patients with obesity and type 2 diabetes or lipodystrophy in order to identify possible targets to mitigate the metabolic alterations caused by the Western diet (WD). Specifically, circulating AGEs levels on the skin will be evaluated and correlated with the stage of sarcopenia in a group of patients with obesity and a T2D diagnosis. Furthermore, the relationship between disease duration and AGE levels will be assessed. A secondary objective will be to analyze the clinical data obtained to identify metabolites and metabolic pathways responsible for the phenotype induced by the WD. The ultimate aim of the study is therefore to verify whether high levels of AGEs are correlated with an early and/or more pronounced onset of sarcopenia, concurrently with an increase in inflammation and oxidative stress.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 195 (estimated)
- First submitted
- 14 May 2024
- Start date
- 15 Jun 2024
- Primary completion date
- 15 May 2026
- Lead sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT06438900
What you commit to
- Study type: Observational
- Planned participants: 195
- From 15 Jun 2024 to the primary completion date, 15 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Secondary obesity or genetic diseases (Prader-Willi Syndrome, Down Syndrome); metabolic and endocrine disorders (Cushing's syndrome, hypothyroidism).
- Subjects with: Inflammatory Bowel Disease (IBD), cancer.
Age
- Age under 18 years.
Other
- Confirmed or planned pregnancy during the study participation months.
Who the study is looking for
- Patients of both sexes.
- Adults.
- BMI compatible with obesity and a diagnosis of type 2 diabetes under good metabolic control (HbA1c \< 7.5%) within 15 years of entry into the study or diagnosis of lipodystrophy (included in the European Consortium of Lipodystrophies (ECLip) Registry (eclip-web.org))
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SCDU Endocrinology, AOU Ospedale Maggiore della Carità Coordinator of this site? Confirm its status | Novara | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.